GENE ONLINE|News &
Opinion
Blog

Go Prime
Novo Nordisk Announces Major Insulin Price Cut by Up to 75%, Following in the Footsteps of Eli Lilly
2023-03-15
Avian Flu H5N1: Fear Over Potential Spread Among Humans and What We Should Know
2023-02-15
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
2023-01-13
The FDA and Biogen Taking Heat for Aduhelm’s Approval Process
2022-12-30
64th ASH Annual Meeting and Exposition: Standard Treatments Face Challenges
2022-12-29
A Force To Be Reckoned With – BioBetter Biologics
2022-12-14
Leveraging Synthetic Biology, Microbiome-based Therapies Open Up Possibilities for Clinical Applications
2022-10-20
Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?
2022-10-12
Mounting Criticisms of FDA’s Accelerated Approval Pathway Could Prompt Changes to the System
2022-08-25
NIH Provides $23 Million to Fund Telehealth Cancer Care Research
2022-08-22
2026: The Promise of Synthetic Biology
2022-08-11
How Governments Around the World Should Respond to the Mounting Costs of Gene and Cell Therapy?
2022-07-08
America’s Ongoing Battle For Lower Insulin Prices
2022-06-23
Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends
2022-05-24
The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products
2022-05-05
1 2 3 11
LATEST
From Sweet to Risky: The Alarming Findings on Sucralose’s Genotoxicity
2023-06-07
GHG Emissions as a ESG Metric
2023-06-07
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
2023-06-07
Krystal Biotech’s First Topical Gene Therapy Approved by FDA
2023-06-06
The Emergence of General AI for Medicine: Medical Applications of ChatGPT
2023-06-06
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023-06-05
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
2023-06-05
Scroll to Top